Modeling long-term health outcomes of patients with cystic fibrosis homozygous for treated with lumacaftor/ivacaftor

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for treated with lumacaftor/ivacaftor

Background: Lumacaftor/ivacaftor combination therapy is efficacious and generally safe for patients with cystic fibrosis (CF) homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation. However, long-term survival benefits of lumacaftor/ivacaftor (LUM/IVA) cannot yet be quanti...

Full description

Bibliographic Details
Main Authors:	Jaime L. Rubin, Lasair O’Callaghan, Christopher Pelligra, Michael W. Konstan, Alexandra Ward, Jack K. Ishak, Conor Chandler, Theodore G. Liou
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-02-01
Series:	Therapeutic Advances in Respiratory Disease
Online Access:	https://doi.org/10.1177/1753466618820186

Similar Items

Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
by: Julie Mésinèle, et al.
Published: (2022-02-01)

The use of targeted therapy lumacaftor/ivacaftor in patients with cystic fibrosis
by: A. G. Chermensky, et al.
Published: (2022-04-01)

Experience of using lumacaftor/ivacaftor in children with cystic fibrosis in the Astrakhan region
by: A. R. Kosareva, et al.
Published: (2022-09-01)

Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
by: Connett GJ
Published: (2019-07-01)

Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
by: Anne H. Neerincx, et al.
Published: (2021-04-01)

Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients
by: Karin Yaacoby-Bianu, et al.
Published: (2022-10-01)

Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects
by: Kelly Kuk, et al.
Published: (2015-12-01)

Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis
by: Stéphanie Bui, et al.
Published: (2021-11-01)

Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data.
by: Lisa J McGarry, et al.
Published: (2023-01-01)

Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data
by: Lisa J. McGarry, et al.
Published: (2023-01-01)

Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor
by: François Arnaud, et al.
Published: (2021-05-01)

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
by: Julian Berges, et al.
Published: (2023-05-01)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
by: Eva Choong, et al.
Published: (2022-08-01)

Clinical Efficacy and Safety of Ivacaftor/Lumacaftor Combination in Patients with Cystic Fibrosis: International Studies Review
by: Nataliya Yu. Kashirskaya, et al.
Published: (2021-12-01)

Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
by: Dolly Sharma, et al.
Published: (2018-09-01)

Bridging for lung transplantation with lumacaftor/ivacaftor
by: Søren Sperling Pedersen, et al.
Published: (2018-06-01)

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation.
by: Kerstin Pohl, et al.
Published: (2018-01-01)

Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging
by: Lena Wucherpfennig, et al.
Published: (2023-04-01)

Short-term effects of Lumacaftor/Ivacaftor (Orkambi™) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosis
by: Bradley S. Quon, et al.
Published: (2020-06-01)

First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial – preliminary results
by: Christian Murer, et al.
Published: (2018-02-01)

Treatment of Cystic Fibrosis Patients Homozygous for <i>F508del</i> with Lumacaftor-Ivacaftor (Orkambi<sup>®</sup>) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
by: Maria Favia, et al.
Published: (2020-03-01)

CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis
by: Olaf Sommerburg, et al.
Published: (2021-03-01)

Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis
by: Elena Stekolchik, et al.
Published: (2022-01-01)

ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor–ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis—an observational study
by: Desmond M Murphy, et al.
Published: (2023-11-01)

The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world setting
by: Paul McNally, et al.
Published: (2023-08-01)

Lumacaftor/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azoles
by: Ikrame Chouchane, et al.
Published: (2019-04-01)

Elexacaftor-Tezacaftor-Ivacaftor in 2 cystic fibrosis adults homozygous for M1101K with end-stage lung disease
by: Winnie M. Leung, et al.
Published: (2023-01-01)

Lumacaftor and Matrine: Possible Therapeutic Combination to Counteract the Inflammatory Process in Cystic Fibrosis
by: Michela Pecoraro, et al.
Published: (2021-03-01)

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
by: Argyri Petrocheilou, et al.
Published: (2020-01-01)

Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation
by: Onofrio Laselva, et al.
Published: (2019-10-01)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
by: Joseph M. Pilewski, et al.
Published: (2020-09-01)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
by: Lijia Zhang, et al.
Published: (2022-12-01)

Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis–Related Diabetes
by: Francis Christian MD, et al.
Published: (2019-04-01)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
by: O&rsquo;Reilly R, et al.
Published: (2013-08-01)

The short-term effects of ORKAMBI (lumacaftor/ivacaftor) on regional and distal lung structures using functional respiratory imaging
by: Eline Lauwers, et al.
Published: (2021-09-01)

Ivacaftor: Five‐year outcomes in the West of Scotland cystic fibrosis population
by: Yasmin Al‐Din, et al.
Published: (2023-05-01)

Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations
by: László Csanády, et al.
Published: (2019-06-01)

Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
by: Shiferaw D, et al.
Published: (2019-08-01)

Analysis of Ivacaftor drug approval for cystic fibrosis patients with gating mutations.
by: Nemirajaiah, S.
Published: (2021-08-01)

Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis
by: Katherine B. Hisert, et al.
Published: (2020-04-01)